Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Different doses of relaxin will be compared to placebo to determine efficacy and safety for
the treatment of patients hospitalized with acute heart failure
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies